Sight Sciences supports the decision announced by five Medicare Administrative Contractors to withdraw their final local coverage determinations for Micro-Invasive Glaucoma Surgery that were scheduled to take effect on January 29, 2024. These five MACs, WPS Government Health Administrators, Palmetto GBA, Celerian Group Company, National Government Services, and Noridian Healthcare Solutions, previously published LCDs on MIGS, which identified certain procedures as investigational for glaucoma management in patients over the age of 18, including canaloplasty in combination with trabeculotomy ab interno, which is a procedural description associated with the Company’s OMNI Surgical System. All five MACs have now issued statements that the final LCDs will not go into effect on January 29, 2024. As a result, there will be no change in January 2024 to the current Medicare coverage for MIGS procedures performed with the OMNI Surgical System.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences (NASDAQ:SGHT) Skyrockets 48% after New Glaucoma News
- Sight Sciences to share results of Sahara RCT vs Restasis with Medicare/payers
- Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
- Sight Sciences announces acceptance for publication of GEMINI 2 trial
- Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
